Silco Pharmaceuticals Limited (DSE:SILCOPHL)
Bangladesh
· Delayed Price · Currency is BDT 14.00
-0.20 (-1.41%)
At close: Apr 28, 2026
Silco Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 431.04 | 431.54 | 410.1 | 464.7 | 559.47 | 601.06 | Upgrade
|
| Revenue Growth (YoY) | 0.31% | 5.23% | -11.75% | -16.94% | -6.92% | -18.07% | Upgrade
|
| Cost of Revenue | 279.67 | 278.5 | 278.25 | 318.76 | 372.72 | 433.3 | Upgrade
|
| Gross Profit | 151.38 | 153.04 | 131.85 | 145.93 | 186.75 | 167.76 | Upgrade
|
| Selling, General & Admin | 63.68 | 64.82 | 62.74 | 69.74 | 80.98 | 80.09 | Upgrade
|
| Other Operating Expenses | -0 | -0 | -0 | -0 | -0 | -0 | Upgrade
|
| Operating Expenses | 73.64 | 74.78 | 72.68 | 78.75 | 89.27 | 88.37 | Upgrade
|
| Operating Income | 77.73 | 78.26 | 59.17 | 67.18 | 97.48 | 79.39 | Upgrade
|
| Interest Expense | -0.45 | -0.65 | -0.93 | -0.2 | -0.53 | -0.76 | Upgrade
|
| Interest & Investment Income | 0.04 | 0.04 | 0.62 | 0.4 | 0.32 | 6.12 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.32 | 1.31 | 1.2 | 3.3 | 5.21 | 4.46 | Upgrade
|
| EBT Excluding Unusual Items | 78.65 | 78.96 | 60.07 | 70.69 | 102.48 | 89.21 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.93 | -0.93 | -0.72 | 18.56 | 6.48 | 0.42 | Upgrade
|
| Pretax Income | 77.72 | 78.03 | 59.35 | 89.24 | 108.96 | 89.63 | Upgrade
|
| Income Tax Expense | 35.32 | 35.38 | 13.47 | 20.02 | 24.51 | 4.98 | Upgrade
|
| Net Income | 42.4 | 42.65 | 45.88 | 69.22 | 84.45 | 84.65 | Upgrade
|
| Net Income to Common | 42.4 | 42.65 | 45.88 | 69.22 | 84.45 | 84.65 | Upgrade
|
| Net Income Growth | -15.07% | -7.04% | -33.72% | -18.03% | -0.23% | 1.77% | Upgrade
|
| Shares Outstanding (Basic) | 103 | 104 | 104 | 104 | 104 | 104 | Upgrade
|
| Shares Outstanding (Diluted) | 103 | 104 | 104 | 104 | 104 | 104 | Upgrade
|
| Shares Change (YoY) | -0.30% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.41 | 0.41 | 0.44 | 0.67 | 0.81 | 0.82 | Upgrade
|
| EPS (Diluted) | 0.41 | 0.41 | 0.44 | 0.67 | 0.81 | 0.82 | Upgrade
|
| EPS Growth | -14.82% | -7.04% | -33.72% | -18.03% | -0.23% | 1.77% | Upgrade
|
| Free Cash Flow | 7.36 | 7.54 | 0.05 | -1.47 | 62.95 | -119.22 | Upgrade
|
| Free Cash Flow Per Share | 0.07 | 0.07 | 0.00 | -0.01 | 0.61 | -1.15 | Upgrade
|
| Dividend Per Share | 0.110 | 0.110 | 0.100 | 0.300 | 0.500 | 1.000 | Upgrade
|
| Dividend Growth | 10.00% | 10.00% | -66.67% | -40.00% | -50.00% | - | Upgrade
|
| Gross Margin | 35.12% | 35.46% | 32.15% | 31.40% | 33.38% | 27.91% | Upgrade
|
| Operating Margin | 18.03% | 18.14% | 14.43% | 14.46% | 17.42% | 13.21% | Upgrade
|
| Profit Margin | 9.84% | 9.88% | 11.19% | 14.90% | 15.10% | 14.08% | Upgrade
|
| Free Cash Flow Margin | 1.71% | 1.75% | 0.01% | -0.32% | 11.25% | -19.84% | Upgrade
|
| EBITDA | 166.98 | 167.29 | 147.77 | 153.9 | 172.16 | 153.98 | Upgrade
|
| EBITDA Margin | 38.74% | 38.77% | 36.03% | 33.12% | 30.77% | 25.62% | Upgrade
|
| D&A For EBITDA | 89.25 | 89.03 | 88.59 | 86.72 | 74.68 | 74.59 | Upgrade
|
| EBIT | 77.73 | 78.26 | 59.17 | 67.18 | 97.48 | 79.39 | Upgrade
|
| EBIT Margin | 18.03% | 18.14% | 14.43% | 14.46% | 17.42% | 13.21% | Upgrade
|
| Effective Tax Rate | 45.45% | 45.35% | 22.70% | 22.44% | 22.49% | 5.56% | Upgrade
|
| Advertising Expenses | - | 3.45 | 3.55 | 3.79 | 4.84 | 6.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.